Indiana’s growth in life sciences jobs beats national average
Bloomington led the nation as the No. 1 small city in medical devices and equipment.
Bloomington led the nation as the No. 1 small city in medical devices and equipment.
The university is hoping to find a private company to take over the 5-year-old facility, which formulated and manufactured
small batches of drugs used in clinical trials.
Indianapolis-based health insurer trades jabs with U.S. health secretary after Reuters story claims insurer deliberately cancels
coverage for breast cancer patients.
The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
The upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought
aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo Inc. bring its artery-measurement
product to market as soon as 2011.
Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.
Indiana University, which has received nearly $600 million from the endowment over the last three decades, will leverage the
new gift to increase its
scientific discoveries and commercialize life science innovations.
FAST Diagnostics LLC said initial human trials on its method to measure kidney function faster and more accurately than existing
techniques could begin as early as next year, with commercialization following by 2012.
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
Previous gifts from the foundation to the cancer center have been used to hire 10 researchers working on breast cancer.
Shareholders are starting to make inroads in their effort to turn struggling West Lafayette-based Bioanalytical Systems Inc. in a new direction.
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
Researchers at IUPUI have been awarded more than $22.3 million in grants by the National Institutes of Health, according to
U.S. Rep. Andre Carson. The money is part of a $5 billion program that was part of the federal stimulus bill approved earlier
this year, and will fund medical research across the country.
Indianapolis-based FAST Diagnostics, a developer of a method to quickly measure kidney function, announced today that it has
received $1 million in federal funding.
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
The pharmaceutical industry—which for two decades has given twice as much in campaign donations
to Republicans as Democrats—organized a panel composed mostly of Democrats this month in Indianapolis
to argue its position on health care reform.
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
Purdue University researcher Philip Low, also the chief science officer for West Lafayette-based Endocyte Inc., has developed
a prostate cancer “homing device” to help anti-cancer agents specifically target prostate
cancer tumors.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it’s developing a potential
competitor to Byetta all on its own.